Thursday, April 23, 2015 10:08:44 AM
Announced positive top-line results from its Phase 2b study of AKB-6548 in non-dialysis patients with anemia related to CKD
Completed enrollment ahead of schedule in the original two cohorts of its Phase 2 study of AKB-6548 in patients with anemia related to CKD who are undergoing dialysis, and added an additional cohort designed to evaluate the safety, efficacy and tolerability of AKB-6548 dosed three times per week, administered in conjunction with a patient's hemodialysis schedule
Presented data from the AKB-6548 development program at the American Society of Nephrology 2014 Annual Meeting and the 2014 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 51st Congress
Strengthened corporate leadership with the addition of Brad Maroni, M.D. as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D. as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources
Added Ronald C. Renaud Jr., Michael Clayman, M.D., Maxine Gowen, Ph.D., and Michael Wyzga to the Board of Directors
Completed an initial public offering and fully exercised underwriters' option to purchase additional shares with net proceeds of the offering totaling $104.4 million
Recent AKBA News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:10 AM
- Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 09/05/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 09/03/2024 08:16:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/03/2024 08:07:59 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/26/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:52:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:18 AM
- Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 08/02/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 07/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 10:05:02 AM
- Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets • PR Newswire (US) • 07/11/2024 10:00:00 AM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 07/01/2024 08:05:00 PM
- Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • PR Newswire (US) • 06/27/2024 12:18:00 PM
- Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer • PR Newswire (US) • 06/24/2024 12:58:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:20:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:19:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:09:32 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 06/03/2024 08:05:00 PM
- Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/23/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:04:58 PM
- Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference • PR Newswire (US) • 05/14/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM